Baxter Likorall Overhead Lift Recall Z-0151-2027 Case Study

Why this case matters

Medical-device recalls are often read as a single event: a firm announces a problem, a regulator classifies it, and the matter is treated as closed. A retrospective look at the recall identified in the headline of this case study, FDA recall Z-0151-2027, concerning Likorall overhead lifts, is instructive precisely because the public record available here does not support that tidy narrative. The documents supplied contain almost no device-specific detail about the Baxter action. What they do contain is a set of regulatory reference pages and unrelated recall entries that illustrate how device and food recalls are recorded and classified, and how carefully a reader has to separate a headline from the evidentiary record behind it.

For readers who follow mass torts and product liability, the distinction matters. A recall classification is a regulatory characterization of the risk and the scope of a corrective action. It is not a finding of negligence, not a court order, and not a determination that any particular patient or caregiver was harmed. The headline for this matter describes a Class II recall over motor shaft breakage and lift strap lowering. Whether that description is borne out by the underlying enforcement record is a question this case study is designed to probe, and the honest answer, on the documents supplied, is that it largely is not.

Overhead patient lifts sit in a category of equipment where the consequences of failure can be severe, which is why recalls in this space attract litigation attention. But the gap between what a recall notice states and what a plaintiff must ultimately prove is wide. A retrospective is the right moment to examine that gap rather than assume it away.

The official record

The supplied documents fall into three groups. The first is the openFDA device enforcement dataset, retrieved with a query limit of five. That document contains a metadata block carrying the agency’s standard disclaimer that the data are not to be relied upon for medical-care decisions and should be assumed unvalidated. It does not contain any record entry naming Baxter, Likorall, or recall Z-0151-2027. The retrieval limit of five results means the dataset as supplied could not have captured a large universe of device recalls in any event, and nothing in the document indicates which entries, if any, were returned.

The second group consists of the openFDA 510(k) dataset, again retrieved with a limit of five, which likewise contains only a metadata and disclaimer block with no substantive entries; the 510(k) premarket notification database page, which describes generally how a 510(k) submission is used to demonstrate substantial equivalence to a legally marketed device under section 513(i)(1)(A) of the FD&C Act, and carries a page-last-updated date of 11/02/2026; and the openFDA device recall dataset, which returns fragmentary entries concerning other firms and products, including Sedecal USA, Inc. and VIASYS, and various openfda identifier arrays. None of those entries concerns the recall at issue.

The third group is contextual rather than evidentiary for the specific product. It includes a Federal Register agency page for the Food and Drug Administration, which describes the agency’s public-health mission and notes that the site is not an official legal edition and that readers doing legal research should verify results against the official edition; and a U.S. Courts statistics page describing the structure of the federal courts. Neither addresses the Baxter recall.

In short, the official record supplied here contains no enforcement entry for recall Z-0151-2027, no product description, no reason-for-recall narrative, no firm name, no date of initiation, no classification date and no termination date.

What the documents establish

Very little can be stated about this specific recall on the strength of these materials, and that limitation should be stated plainly rather than papered over.

First, the documents do not establish that recall Z-0151-2027 exists as a matter of record. The identifier appears in the article headline provided for this case study, but no supplied document contains it. A recall number is a specific data element in the openFDA enforcement schema, and none of the entries returned carries this number.

Second, the documents do not state the recalling firm’s identity, the product’s model or catalog numbers, the number of units affected, the geographic distribution, or the dates of initiation, classification or termination. The record does not state a figure for any of these. Where the headline refers to motor shaft breakage and lift strap lowering, no supplied document contains language describing either failure mode, and no supplied document assigns the action a Class II designation.

Third, the documents do not describe any injury, adverse event, patient harm, lawsuit, settlement, verdict or regulatory penalty connected to this product. The openFDA disclaimers in the supplied records speak generally about contamination and infection in the context of sterile-barrier compromise, which is standard boilerplate attached to the dataset rather than a finding about overhead lifts.

Fourth, the documents do not establish that any civil claim has been filed, consolidated or resolved. The U.S. Courts page describes the federal court system in general terms; it reports no statistics for any device matter.

What the documents do establish is procedural background. They confirm that FDA maintains public databases for device enforcement, device recalls and 510(k) premarket notifications, that these datasets carry accuracy disclaimers, and that a 510(k) is a substantial-equivalence submission under a specific statutory provision. They also confirm that Federal Register content published on the prototype site is not the official legal edition. Those are useful framing points for a reader assessing any recall record, but they are not findings about Baxter or Likorall.

How a claim of this kind is assessed

Device-injury claims generally proceed along a different track from the regulatory recall process, and the two run on separate clocks. A recall is an administrative action in which a firm identifies a problem, proposes a correction or removal, and FDA assigns a classification reflecting the probability of serious adverse health consequences. A civil claim, by contrast, turns on the plaintiff’s own injury, the mechanism of failure, the state of the device at the time of the incident, and the legal theories available in the relevant jurisdiction.

In practice, counsel evaluating an overhead-lift matter typically work backward from the incident. They seek the device’s identification and service history, the maintenance and inspection log, the recall notice and any field correction documentation, the firm’s communications to customers, and the regulatory correspondence. The recall record, if it can be located and verified, functions as one piece of evidence about what the manufacturer knew and when, not as proof of causation. A recall classification is a regulatory characterization; it does not establish that a particular lift failed, that a particular failure caused a particular injury, or that any duty was breached.

The distinction between a Class I, Class II and Class III designation matters to how a matter is framed, because the classification reflects the agency’s assessment of the probability of serious adverse health consequences. On the documents supplied here, no classification is recorded for this product, so nothing can be said about how the agency characterized the risk.

The documents also contain nothing on whether any claim has been filed, whether any matter has been consolidated before a single judge, or whether any resolution has occurred. There is no docket number, no court, no settlement figure and no verdict in the supplied record. Readers should treat any account that supplies those details as resting on a source outside these documents.

What to check before relying on any figure

The central caution for this case study is that a headline is not a record. The title provided for this article asserts a recall number, a firm, a product line, a class and two failure modes. Each of those is a checkable data element, and each can be verified against the agency’s own enforcement record rather than inferred. A reader assessing the matter should confirm the recall number against the enforcement dataset directly, and should confirm that the returned entry matches the firm, the product and the stated reason for recall.

The recall number format itself is a useful check. Entries in the device recall dataset supplied here use a Z-prefix for device recalls, as distinct from the F-prefix used in the food enforcement entries in the same set of documents. A number that does not follow the expected pattern, or that cannot be matched to an entry, warrants scrutiny before it is repeated.

Dates deserve the same care. The record supplied here does not state an initiation date, a classification date or a termination date for this recall, and the documents do not state a figure for units affected, distribution scope or the number of devices in service. Where a later account supplies such figures, they should be traced to the specific enforcement entry rather than to secondary reporting.

Finally, readers should keep the regulatory and civil questions separate. Even a fully verified Class II recall entry would establish only that the agency classified a corrective action at a particular level. It would not establish injury, liability or any entitlement to compensation, and no document supplied here supports any statement about the likelihood of recovery in any individual matter. The record, as it stands, supports a narrow conclusion: the databases exist, the disclaimers apply, and the specific entry has yet to be produced.

Sources

• U.S. Food and Drug Administration
• U.S. Food and Drug Administration
• U.S. Food and Drug Administration
• 510(k) Premarket Notification
• Federal Register :: Agencies - Food and Drug Administration
• U.S. Food and Drug Administration
• Data & News